Skip to main content
. 2016 May 3;63(3):414–422. doi: 10.1093/cid/ciw291

Figure 3.

Figure 3.

Cumulative risk of recurrent malaria by day 42 following treatment with artemether-lumefantrine stratified by human immunodeficiency virus (HIV) status and a day 7 lumefantrine concentration of 200 ng/mL. Includes children from intensive and sparse cohorts. Risk-adjusted for repeated measures, age, parasite density, and hemoglobin on day 0.